HLA-G - From fetal tolerance to a regulatory molecule in inflammatory diseases

Current Immunology Reviews

Volumn 6, Issue 1, 2010, Pages 1-15

  Veit, Tiago Degani ^a   Vianna, Priscila ^a   Chies, José Artur B ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cancer; Genetics; HLA G; Immune regulation; Inflammatory diseases; Pregnancy

Indexed keywords

HLA G ANTIGEN;

ANTIGEN EXPRESSION; DNA POLYMORPHISM; DNA SPLICING; FETOPLACENTAL UNIT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATORY DISEASE; NEOPLASM; NIDATION; NONHUMAN; ORGAN TRANSPLANTATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS; VIRUS INFECTION;

EID: 77949663417     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510790231806     Document Type: Review

References (190)

1. Hughes AL, Nei M. Evolution of the major histocompatibility complex: independent origin of nonclassical class I genes in different groups of mammals. Mol Biol Evol 1989; 6: 559-79.
2. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci USA 1987; 84: 9145-9.
3. Ellis SA, Palmer MS, McMichael AJ. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA Class I molecule. J Immunol 1990; 144: 731-5.
4. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. Class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248: 220-3.
5. Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510-5.
6. Ishitani A, Sageshima N, Lee N, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 2003; 171: 1376-84.
7. Clements CS, Kjer-Nielsen L, McCluskey J, Rossjohn J. Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol 2007; 68: 220-6.
8. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81: 199-252.
9. Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000; 355:2138.
10. Morales PJ, Pace JL, Platt JS, et al. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 2003; 171: 6215-24.
11. Rouas-Freiss N, Bruel S, Menier C, Marcou C, Moreau P, Carosella ED. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer 2005;117: 114-22.
12. Kirszenbaum M, Moreau P, Gluckman E, Dausset J, Carosella E. An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci USA 1994; 91: 4209-13.
13. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling bothclass I and class II antigens. Proc Natl Acad Sci USA 1992; 89: 3947-51.
14. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLAG antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994; 153: 5516-24.
15. Moreau P, Carosella E, Teyssier M, et al. Soluble HLA-G molecule. An alternatively spliced HLA-G mRNA form candidate to encode it in peripheral blood mononuclear cells and human trophoblasts. Hum Immunol 1995; 43: 231-6.
16. Paul P, Cabestre FA, Ibrahim EC, et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLAG5,- G6, and-G7 transcripts in human transfected cells. Hum Immunol 2000; 61: 1138-49.
17. Park B, Lee S, Kim E, Chang S, Jin M, Ahn K. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity 2001; 15: 213-24.
18. Wilczynski JR. Th1/Th2 cytokines balance yin and yang of reproductive immunology. Eur J Obstet Gynecol Reprod Biol 2005;122: 136-43
19. Chaouat G, Ledee-Bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J. TH1/TH2 paradigm in pregnancy: Paradigm lost? Cytokines in pregnancy/early abortion: Reexamining the TH1/ TH2 paradigm. Int Arch Allergy Immunol 2004;134: 93-119.
20. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14: 353-6.
21. Hofmeister V, Weiss EH. HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol 2003;13: 317-23.
22. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997; 94: 11520-5.
23. Moreau P, Adrian-Cabestre F, Menier C, et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 11: 803-11.
24. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 1997; 94: 5249-54.
25. Le Gal FA, Riteau B, Sedlik C, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11: 1351-6.
26. Riteau B, Menier C, Khalil-Daher I et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 2001; 13: 193-201.
27. Menier C, Riteau B, Carosella ED, Rouas-Freiss N. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 2002; 100: 63-70.
28. Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol 2003; 13: 325-36.
29. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 1999; 43: 203-11.
30. Bahri R, Hirsch F, Josse A, et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 2006;176:1331-9.
31. LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: Cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109: 2040-8.
32. Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007; 26:1423-33.
33. Horuzsko A, Lenfant F, Munn DH, Mellor AL. Maturation of antigen presenting cells is compromised in HLA-G transgenic mice. Int Immunol 2001;13: 385-94.
34. Borges L, Cosman D. LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine Growth Factor Ver 2000; 11: 209-17.
35. Colonna M, Navarro F, Bellón T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809-18.
36. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol 1997; 159: 5192-6.
37. Allan DS, Colonna M, Lanier LL, et al. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med 1999; 189: 1149-56.
38. Shiroishi M, Tsumoto K, Amano K, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 2003; 100: 8856-61.
39. Shiroishi M, Kuroki K, Rasubala L, et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 2006; 103: 16412-7.
40. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLAA2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003; 4: 913-9.
41. Clements CS, Kjer-Nielsen L, Kostenko L, et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 2005; 102: 3360-5.
42. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 2007; 37: 1924-37.
43. Boyson JE, Erskine R, Whitman MC, et al. Disulfide bondmediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 2002; 99:16180-5.
44. Shiroishi M, Kuroki K, Ose T, et al. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006; 281:10439-47.
45. Gonen-Gross T, Achdout H, Gazit R, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003; 171:1343-51.
46. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999; 189: 1093-100.
47. Rajagopalan S, Bryceson YT, Kuppusamy SP, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006; 4: e9.
48. Ponte M, Cantoni C, Biassoni R, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci USA 1999; 96: 5674-9.
49. Goodridge JP, Lathbury LJ, Steiner NK, et al. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol 2007; 37: 199-211.
50. Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol 2002; 168: 5047-57.
51. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J Immunol 2005; 174: 3859-63.
52. Cantoni C, Verdiani S, Falco M, et al. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. Eur J Immunol 1998; 28:1980-90.
53. Yan WH, Fan LA. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res 2005; 15: 176-82.
54. Yu YR, Tian XH, Wang Y, Feng MF. Rapid production of human KIR2DL4 extracellular domain and verification of its interaction with HLA-G. Biochemistry (Mosc) 2006; 71:S60-4, 4-5.
55. Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol 2008; 29:313-21.
56. Clements CS, Kjer-Nielsen L, McCluskey J, Rossjohn J. Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol 2007; 68: 220-6.
57. Zavazava N, Krönke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2:1005-10.
58. Puppo F, Contini P, Ghio M, et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8 (+) Fas (CD95) (+) T lymphocytes. Int Immunol 2000; 12: 195-203.
59. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A,-B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33: 125-34.
60. Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164: 6100-4.
61. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 2007; 17: 469-79.
62. Mandelboim O, Pazmany L, Davis DM, et al. Multiple receptors for HLA-G on human natural killer cells. Proc Natl Acad Sci USA 1997; 94:14666-70.
63. Münz C, Holmes N, King A, et al. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J Exp Med 1997; 185: 385-91.
64. Fons P, Chabot S, Cartwright JE, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006;108: 2608-15.
65. Barakonyi A, Rabot M, Marie-Cardine A, et al. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol 2004; 173: 5349-54.
66. Llano M, Lee N, Navarro F, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998; 28: 2854-63.
67. Carosella ED, Howangyin KY, Favier B, Lemaoult J. HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol 2008; 69(11): 700-7.
68. Feger U, Tolosa E, Huang YH, et al. HLA-G expression defines a novel regulatory T cell subset present in human peripheral blood and sites of inflammation. Blood 2007: 110: 568-77.
69. Le Rond S, Le Maoult J, Créput C, et al. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol 2004; 34: 649-60.
70. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism Proc Natl Acad Sci USA 2001; 98: 12150-5.
71. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4 T cells. Proc Natl Acad Sci USA 2004; 101: 7064.
72. Le Rond S, Azema C, Krawice-Radanne I, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 2006;176: 3266-76.
73. Naji A, Le Rond S, Durrbach A, et al. CD3CD4low and CD3CD8low are induced by HLA-G. Novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007; 110: 3936-48.
74. Liang S, Horuzsko A. Mobilizing dendritic cells for tolerance by engagement of immune inhibitory receptors for HLA-G. Hum Immunol 2003; 64:1025-32.
75. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005; 35:1133-42.
76. Créput C, Durrbach A, Menier C, et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003; 39: 587-94.
77. Pangault C, Le Friec G, Caulet-Maugendre S, et al. Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol 2002; 63: 83-90.
78. Khosrotehrani K, Le Danff C, Reynaud-Mendel B, Dubertret L, Carosella ED, Aractingi S. HLA-G expression in atopic dermatitis. J Invest Dermatol 2001; 117: 750-2.
79. Lozano JM, González R, Kindelán JM et al. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS 2002; 16: 347-51.
80. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105:1694-8.
81. Selmani Z, Naji A, Zidi I, et al. HLA-G5 secretion by human mesenchymal stem cells is required to suppress T-lymphocyte and NK function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-22.
82. Selmani Z, Naji A, Gaiffe E, et al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87: S62-6.
83. Huang J-F, Yang Y, Sepulveda H, et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 286: 952-4.
84. Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol 2001; 166: 3645-9.
85. Patel DM, Arnold PY, White GA, Nardella JP, Mannie MD. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 1999; 163: 5201-10
86. Tatari-Calderone Z, Semnani RT, Nutman TB, Schlom J, Sabzevari H. Acquisition of CD80 by human T Cells at early stages of activation: functional involvement of CD80 acquisition in Tcell to T cell interaction. J Immunol 2002; 169: 6162-9.
87. Game DS, Rogers NJ, Lechler RI. Acquisition of HLA-DR and costimulatory molecules by T cells from allogeneic antigen presenting cells. Am J Transplant 2007; 7: 1614-25
88. Sabzevari H, Kantor J, Jaigirdar A, et al. Acquisition of CD80 (B7-1) by T Cells. J Immunol 2001; 166: 2505-13.
89. Sjostrom A, Eriksson M, Cerboni C, et al. Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors. J Exp Med 2001; 194: 1519-30.
90. Tabiasco J, Vercellone A, Meggetto F, Hudrisier D, Brousset P, Fournie JJ. Acquisition of viral receptor by NK cells through immunological synapse. J Immunol 2003; 170: 5993-8.
91. Vanherberghen B, Andersson K, Carlin LM, et al. Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci USA 2004; 101: 16873-8.
92. Zimmer J, Ioannidis V, Held W. H-2D ligand expression by Ly49A+ natural killer (NK) cells precludes ligand uptake from environmental cells: implications for NK cell function. J Exp Med 2001; 194:1531-9.
93. Carlin LM, Eleme K, McCann FE, Davis DM. Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses. J Exp Med 2001; 194:1507-17.
94. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 2000; 61: 1102-7.
95. Solier C, Mallet V, Lenfant F, Bertrand A, Huchenq A, Le Bouteiller P. HLA-G unique promoter region: functional implications. Immunogenetics 2001; 53: 617-25.
96. Ibrahim EC, Morange M, Dausset J, Carosella ED, Paul P. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 2000; 5: 207-18.
97. Bamberger AM, Jenatschke S, Schulte HM, Löning T, Bamberger MC. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab 2000; 85: 3932-6.
98. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol 1996; 156: 4224-31.
99. Lefebvre S, Berrih-Aknin S, Adrian F, et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem 2001; 276: 6133-9.
100. Amiot L, Onno M, Drénou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol 1998; 59: 524-8.
101. Moreau P, Faure O, Lefebvre S, et al. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc 2001; 33: 2277-80.
102. Yie SM, Li LH, Li GM, Xiao R, Librach CL. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod 2006; 21: 46-51.
103. Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum Reprod 2006; 21: 2538-44.
104. Ober C, Aldrich CL, Chervoneva I, et al. Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet 2003; 72: 1425-35.
105. Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet 2005; 14: 3619-28.
106. Ober C, Billstrand C, Kuldanek S, Tan Z. The miscarriageassociated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum Reprod 2006; 21:1743-8.
107. Aldrich C, Wambebe C, Odama L, Di Rienzo A, Ober C. Linkage disequilibrium and age estimates of a deletion polymorphism (1597??C) in HLA-G suggest non-neutral evolution. Hum Immunol 2002; 63: 405-12.
108. Pfeiffer KA, Fimmers R, Engels G, van Der Ven H, van Der Ven K. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. Mol Hum Reprod 2001; 7: 373-8.
109. Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 2003; 100: 1191-6.
110. Mouillot G, Marcou C, Zidi I, et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007, 68: 277-285.
111. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. The 14 bp deletion-insertion polymorphism in the 3'UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003; 64:1005-10.
112. Hviid TV, Hylenius S, Rørbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003; 55: 63-79.
113. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics 2004; 56: 135-41.
114. Rizzo R, Hviid TV, Stignani M, et al. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics 2005; 57:172-81.
115. Rizzo R, Rubini M, Govoni M, et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics 2006; 16: 615-23.
116. Rizzo R, Hviid TV, Govoni M, et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens 2008; 71: 520-9.
117. Tan Z, Randall G, Fan J, et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet 2007; 81: 829-34.
118. Veit TD, Chies JA. Tolerance versus immune response - MicroRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol 2009; 20: 229-231.
119. Yie SM, Li LH, Xiao R, Librach CL. A single base-pair mutation in the 3'-untranslated region of HLA-G mRNA is associated with pre-eclampsia. Mol Hum Reprod. 2008; 14(11): 649-53.
120. Tripathi P, Abbas A, Naik S, Agrawal S. Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. Tissue Antigens 2004; 64: 706-10.
121. Hviid TV. HLA-G in human reproduction: Aspects of genetics, function and pregnancy complications. Hum Reprod Update 2006; 12: 209-32.
122. Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001; 57:15-21.
123. Yie SM, Taylor RN, Librach C. Low plasma HLA-G protein concentrations in early gestation indicate the development of preeclampsia later in pregnancy. Am J Obstet Gynecol 2005;193: 204-8.
124. Vianna P, Dalmaz CA, Veit TD, et al. Immunogenetics of pregnancy: role of a 14-bp deletion in the maternal HLA-G gene in primiparous pre-eclamptic Brazilian women. Hum Immunol 2007; 68: 668-74.
125. Pregnancy WGRoHBPi. Report of the National high Blood Pressure Education Program. Am J Obstet Gynecol 2000; 183: S1
126. Goldman-Wohl DS, Ariel I, Greenfield C, et al. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with preeclampsia. Mol Hum Reprod 2000; 6: 88-95.
127. Hara N, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: Immunohistological demonstration with anti-HLA-G specific antibody "87G" and anticytokeratin antibody "CAM5.2". Am J Reprod Immunol 1996; 36: 349-58.
128. Lim KJ, Odukoya OA, Li TC, Cooke ID. Cytokines and immunoendocrine factors in recurrent miscarriage.. Hum Reprod Update 1996; 2: 469-81.
129. Le Bouteiller P, Pizzato N, Barakonyi A, Solier C. HLA-G, preeclampsia, immunity and vascular events. J Reprod Immunol 2003; 59: 219.
130. Yao YQ, Barlow DH, Sargent IL. Differential expression of alternatively spliced transcripts of HLA-G in human preimplantation embryos and inner cell masses. J Immunol 2005; 175: 8379-85.
131. Menezo Y, Elder K, Viville S. Soluble HLA-G release by the human embryo: An interesting artefact? Reprod Biomed Online 2006;13: 763-4.
132. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005; 65:10139-44.
133. Luque J, Torres MI, Aumente MD, et al. sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation. Transplant Immunol. 2006; 17: 70-73.
134. Lila N, Amrein C, Guillemain R, Chevalier P, Fabiani J-N, Carpentier A. Soluble human leukocyte antigen-G: a new strategy for monitoring acute and chronic rejections after heart transplantation. J Heart Lung Transplant 2007; 26: 421-2.
135. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6: 2152-6.
136. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111:4862-70.
137. Bukur J, Rebmann V, Grosse-Wilde H, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63: 4107-11.
138. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168: 4772-80.
139. Singer G, Rebmann V, Chen YC et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9: 4460-4.
140. Ibrahim EC, Aractingi S, Allory Y, et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 2004;108: 243-50.
141. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007; 20:375-83.
142. Morandi F, Levreri I, Bocca P et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007; 67: 6433-41.
143. Sebti Y, Le Maux A, Gros F, et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol. 2007;138: 202-12.
144. Schwartz EJ, Neumann AU, Teixeira AV, et al. Effect of target cell availability on HIV-1 production in vitro. AIDS 2002; 16: 341-5.
145. Navikas V, Link J, Persson C, et al. Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retroviruses 1995; 9: 484-9.
146. Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol 2000; 74: 6808-20.
147. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol 2000; 164: 6426-34.
148. Lajoie J, Hargrove J, Zijenah LS, Humphrey JH, Ward BJ, Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis 2006; 193: 298-301.
149. Matte C, Lajoie J, Lacaille J, Zijenah LS, Ward BJ, Roger M. Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS 2004; 18: 427-31.
150. Fabris A, Catamo E, Segat L, et al. Association between HLA-G 3'UTR 14-bp polymorphism and HIV vertical transmission in Brazilian children. AIDS 2009; 23(2): 177-82.
151. Martinetti M, Pacati I, Cuccia M, et al. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol 2006; 19(2): 369-78.
152. Cordero EAA, Veit TD, da Silva MAL, Jacques SMC, Silla LMR Chies JAB. HLA-G polymorphism influences the susceptibility to HCV infection in sickle cell disease patients. Tissue Antigens 2009. [in press]
153. Zheng XQ, Zhu F, Shi WW, Lin A, Yan WH. The HLA-G 14 bp insertion/deletion polymorphism is a putative susceptible factor for active human cytomegalovirus infection in children. Tissue Antigens 2009. [in press]
154. Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 2000; 48: 679-84.
155. Aractingi S, Briand N, Le Danff C, et al. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol 2001; 159: 71-7.
156. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000; 101:191-200.
157. Kanai T, Fujii T, Unno N, et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol 2001; 45: 94-9.
158. Kanai T, Fujii T, Kozuma S, et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol. Hum. Reprod 2001; 7:195-200.
159. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001; 22: 553-5.
160. Torres MI, Le Discorde M, Lorite P, et al. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int Immunol 2004; 16: 579-83.
161. Rizzo R, Melchiorri L, Simone L, et al. Different production of soluble HLA-G antigens by peripheral blood mononuclear cells in ulcerative colitis and Crohn's disease: a noninvasive diagnostic tool? Inflamm Bowel Dis. 2008;14: 100-5.
162. Glas J, Török HP, Tonenchi L, et al. The 14-bp deletion polymorphism in the HLA-G gene displays significant differences between ulcerative colitis and Crohn's disease and is associated with ileocecal resection in Crohn's disease. Int Immunol 2007;19: 621-6.
163. Torres MI, López-Casado MA, Luque J, Peña J, Ríos A. New advances in coeliac disease: serum and intestinal expression of HLA-G. Int Immunol 2006; 18: 713-8.
164. Ciprandi G, Contini P, Murdaca G, DeAmici M, Gallina AM, Puppo F. Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. Int Immunopharmacol. 2009; 9(9): 1058-62.
165. Ciprandi G, Contini P, Murdaca G, Gallina AM, Puppo F. Soluble HLA-G Molecule in Patients with Perennial Allergic Rhinitis. Int Arch Allergy Immunol. 2009; 150(3): 278-81.
166. Mitsdoerffer M, Schreiner B, Kieseier BC, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005; 159: 155-64.
167. Fainardi E, Rizzo R, Melchiorri L, et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol 2003; 142:149-58.
168. Fainardi E, Rizzo R, Melchiorri L, et al. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler 2006; 12: 2-12.
169. Fainardi E, Rizzo R, Melchiorri L, et al. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis. Mult Scler 2008; 14: 446-54.
170. Kroner A, Grimm A, Johannssen K, Mäurer M, Wiendl H. The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis. Hum Immunol 2007; 68: 422-5.
171. Verbruggen LA, Rebmann V, Demanet C, De Cock S, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. Hum Immunol 2006; 67: 561-7.
172. Veit TD, Vianna P, Scheibel I, et al. Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis. Tissue Antigens 2008; 71: 440-6.
173. Stamp LK, O'Donnell JL, Chapman PT, et al. Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann Rheum Dis. 2009; 68(1): 154-5.
174. Wastowski IJ, Sampaio-Barros PD, Amstalden EM, et al. HLA-G expression in the skin of patients with systemic sclerosis. J Rheumatol. 2009; 36(6): 1230-4.
175. Monneret G, Voirin N, Krawice-Radanne I, et al. Soluble human leukocyte antigen-G5 in septic shock: marked and persisting elevation as a predictor of survival. Crit Care Med 2007; 35: 1942-7.
176. Nicolae D, Cox NJ, Lester LA, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005; 76: 349-57.
177. Hersh CP, Raby BA, Soto-Quirós ME, et al. Comprehensive testing of positionally cloned asthma genes in two populations. Am J Respir Crit Care Med 2007; 176: 849-57.
178. Tahan F, Patiroglu T. Plasma soluble human leukocyte antigen G levels in asthmatic children. Int Arch Allergy Immunol 2006; 141: 213-6.
179. Rizzo R, Mapp CE, Melchiorri L, et al. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. J Allergy Clin Immunol 2005; 115: 508-13.
180. Mapp CE, Ferrazzoni S, Rizzo R, et al. Soluble human leucocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma. Clin Exp Allergy. 2009; 39(6): 812-9.
181. Rosado S, Perez-Chacon G, Mellor-Pita S, et al.. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol 2008; 69: 9-15.
182. Veit T, Cordero E, Mucenic T, et al. Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus 2009; 18: 424-30.
183. Eike MC, Becker T, Humphreys K, Olsson M, Lie BA. Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun. 2009;10(1): 56-67.
184. Kim JJ, Hong SJ, Hong YM, et al. Genetic variants in the HLA-G region are associated with Kawasaki disease. Hum Immunol. 2008; 69(12): 867-71.
185. Hviid TV, Milman N, Hylenius S, Jakobsen K, Jensen MS, Larsen LG. HLA-G polymorphisms and HLA-G expression in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 30-7.
186. Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES. HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease. Tissue Antigens 2007; 69:139-44.
187. Lin A, Yan WH, Xu HH, et al. 14 bp deletion polymorphism in the HLA-G gene is a risk factor for idiopathic dilated cardiomyopathy in a Chinese Han population. Tissue Antigens 2007; 70: 427-31.
188. Gazit E, Slomov Y, Goldberg I, Brenner S, Loewenthal R. HLA-G is associated with pemphigus vulgaris in Jewish patients. Hum Immunol 2004; 65:39-46.
189. Yari F, Zavaran Hosseini A, Nemat Gorgani M, Khorramizadeh MR, Mansouri P, Kazemnejad A. Expression of HLA-G in the skin of patients with pemphigus vulgaris. Iran J Allergy Asthma Immunol 2008; 7: 7-12.
190. LeMaoult J, Le Discorde M, Rouas-Freiss N, et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003; 62: 273-84.